BS-001

DB17415InvestigationalGene Therapies

BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor, Granulocyte-macrophage colony-stimulating factor, and T-cell surface glycoprotein CD3
Curator reviewed
Code names: BS-001 · OH2

Resolves to

Targets

What you can answer from here — as of July 10, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with BS-001, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.